




IMMUNE SAFETY AVATAR

Nonclinical mimicking of the immune system effects of immunomodulatory therapies



Deliverable 2.2 Preliminary irAOP - CPI MoA

DELIVERABLE REPORT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988.

The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.



Abstract

Within imSAVAR, we follow the strategy to define immune-related adverse outcome pathways (irAOPs) to guide the development of novel test systems. Adverse Outcome Pathways (AOPs) are a conceptual framework to support research teams of diverse expertise to describe the current knowledge of biological effects triggered by an initiating event leading to adverse health effects (Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways; available online at <https://www.oecd-ilibrary.org/content/paper/5jlv1m9d1g32-en>). In detail, AOPs describe the link between a molecular initiating event (MIE) and a series of key events (KEs), i.e. measurable and critical biological events, at different response levels (e.g. molecular, cellular, organ, organism) leading to adverse health effects [1]. In the context of immunomodulatory therapeutics, we interpret irAOPs as the link between a certain Mode of Action (MoA) interacting with the immune system and a series of key events (KEs) at different organisational levels of the immune system leading to an adverse immune response. Terminology of irAOPs comprises Mode of Action (MoA), key event (KE), key event relationship (KER), and adverse outcome (AO).

Document Information

Deliverable Report	D2.2: Preliminary irAOP - CPI MoA
Date	30.09.2020
Report prepared by	Covance Laboratories Ltd Universitaetsklinikum Wuerzburg – Klinikum der Bayerischen Julius-Maximilians-Universitaet, Novartis Pharma AG, MERCK SHARP & DOHME CORP
Project	imSAVAR - Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies Grant Agreement No.: 853988 (IMI2-2018-15-04)
Project Coordinator	Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V. Prof. Dr. Dr. Ulrike Köhl Novartis Pharma AG Dr. Jonathan Moggs
Type	Deliverable Report Public

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.



Table of Contents

Abstract 2

1. Methods 5

2. Results 5

3. Discussion 5

4. Conclusion 5

References 5

Acknowledgement..... 6

1. Methods

Based on the OECD Guidance Document for developing and assessing AOPs, we developed a preliminary irAOP for the MoA CPI (immune checkpoint inhibitors, e.g. anti-CTLA4 or anti-PD1) and the adverse outcome Cytokine Release Syndrome (CRS).

2. Results




Figure 1: Preliminary irAOP for MoA CPI and adverse outcome CRS

3. Discussion

To further develop and refine the preliminary irAOP for CPI, we will discuss the current framework with all partners working on CPI-based projects, also during the upcoming 2nd imSAVAR workshop. The results of these discussions will provide additional information for the currently available test systems (in vitro and in vivo) and will help to refine the irAOP for CPI and will also help to build irAOPs for additional adverse outcomes associated with CPI therapy.

4. Conclusion

The irAOP for MoA CPI and adverse outcome CRS will guide the development of novel test systems to assess the (proposed) KEs that finally lead to CRS. Furthermore, the continuous improvement of the irAOPs will also provide a better insight on the existing gaps in these AOPs.

References

1. Ankley, G.T., et al., *Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment*. Environ Toxicol Chem, 2010. **29**(3): p. 730-41.

Acknowledgement

The authors would like to express their gratitude to the Innovative Medicines Initiative 2 Joint Undertaking (JU) for the financial support of this research under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.

